Weathering the Storm: Fortis Advisors' Q4 2022 vs. Q1 2023 13F Holdings Comparison

Fortis Advisors, LLC recently released their Q4 2022 and Q1 2023 13F holdings comparison report, revealing significant changes to their portfolio. As the market continues to experience unprecedented volatility, it's crucial to understand the shifts in holdings of one of the industry's leading firms.

One of the most drastic changes in Fortis Advisors' portfolio is the Vanguard Ultra-Short Bond ETF (VUSB), which saw a 61.2% increase in shares from Q4 2022 to Q1 2023. The move likely reflects a desire for fixed-income assets with minimal risk. Another Vanguard fund that saw an increase in holdings was the Vanguard Short-Term Bond ETF (BSV), which grew by 14.3% over the same period.

Fortis Advisors' holdings in the Vanguard FTSE Developed Markets ETF (VEA) declined by 17.4%. This reduction may be due to concerns about economic conditions in foreign markets or an attempt to rebalance the portfolio. The SPDR DoubleLine Total Return Tactical ETF (TOTL) saw a massive increase in shares, growing from 37,618 in Q4 2022 to 195,591 in Q1 2023. This shift could signal a bet on a further rise in bond prices.

The moves also included some interesting individual picks. The Seagate Technology Holdings Plc Ord Shs stock (STX) saw an increase in value by 25.7% from Q4 2022 to Q1 2023, reflecting a growing interest in information technology stocks amid the pandemic. Meanwhile, FedEx Corp Com (FDX) grew by 31.9% in value, reflecting the continued growth in e-commerce brought on by the pandemic.

Fortis Advisors' holdings in the Disney Walt Co Com (DIS) increased by 43.4%, suggesting the firm is bullish on the entertainment conglomerate's long-term prospects. The Amazon Com Inc Com (AMZN) stock also grew in value by 23%, reflecting Fortis Advisors' conviction in the e-commerce behemoth's prospects despite antitrust overhang.

In contrast, Fortis Advisors reduced its holdings in some of the previously popular stocks. The Vanguard Health Care ETF (VHT) saw a decline in shares from 46,448 in Q4 2022 to 41,724 in Q1 2023 – a decline of 21.6%. Similarly, CVS Health Corp Com (CVS) saw a decline in value by 20.3%, likely due to increasing competition from new players entering the healthcare market.

It's important to note that these changes are by no means a comprehensive review of Fortis Advisors' portfolio or investment strategy. However, they offer valuable insights into the thinking of one of the industry's most prominent firms during what remains a challenging period for investors. As always, investors should conduct their due diligence before making any investment decisions.